Strand Therapeutics

Strand Therapeutics has developed a drug candidate made of self-replicating mRNA that can make cancers more responsive to immunotherapy. Its synthetic mRNA programming technology makes its drug candidate safer than other gene therapies, more effective in patients, and cheaper to manufacture.

Strand Therapeutics is a business in prime based in Boston, Massachusetts, US, founded in 2017.

Within the prime space, the company focuses on its core offering rather than a broad product line.

Boston, Massachusetts, US is where the company is located.

Its current recorded stage is Creative Destruction Lab alumni company.

Its team size is recorded as 51-200 employees.

Website: strandtx.com